» Tolerx Announces Achievement Of Milestones Upon Anti-CD4 Antibody Program Advancement And Initiation Of Phase 1 Clinical Trial
Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced that Genentech, a collaborator, has…